What is Bionyra Pharma?
Bionyra Pharma operates as a clinical-stage biotechnology enterprise dedicated to the discovery and development of next-generation biologic therapies. The company distinguishes itself through a specialized focus on monoclonal and multispecific antibody programs, which are engineered to modulate key immune pathways with high specificity. By targeting the underlying mechanisms of inflammatory diseases, such as inflammatory bowel disease and atopic dermatitis, Bionyra Pharma aims to provide patients with deeper and more durable therapeutic outcomes. Its market position is defined by a rigorous scientific approach to antibody engineering, positioning the firm as a significant player in the competitive landscape of immunology and chronic disease management.
How much funding has Bionyra Pharma raised?
Bionyra Pharma has raised a total of $165M across 1 funding round:
Series A
$165M
Series A (2026): $165M with participation from Sanofi Ventures, Sofinnova Partners, Sixty Degree Capital, Arkin Holdings, Apollo Health Ventures, Jeito, and Vives
Key Investors in Bionyra Pharma
Sanofi Ventures
Sanofi Ventures is the corporate venture capital arm of Sanofi, focusing on early-stage biotech and digital health companies with transformative technologies in immunology and rare diseases.
Sofinnova Partners
A leading European venture capital firm in life sciences that acts as a hands-on company builder, supporting entrepreneurs from seed to later-stage development.
Sixty Degree Capital
A global investment firm specializing in healthcare and technology, providing strategic backing to high-potential companies across the drug development and digital health spectrum.
What's next for Bionyra Pharma?
Following this major enterprise-level funding, Bionyra Pharma is expected to prioritize the expansion of its clinical pipeline and the scaling of its manufacturing capabilities. The strategic deployment of these funds will likely focus on advancing lead candidates through Phase II trials, while simultaneously bolstering the company's internal R&D infrastructure. By leveraging the expertise of its high-profile investor syndicate, the firm is poised to navigate the complexities of global regulatory pathways and accelerate the delivery of its innovative biologic solutions to patients. Future growth will likely center on establishing strategic partnerships to enhance the commercial viability of its multispecific antibody portfolio.
See full Bionyra Pharma company page
